Items Tagged ‘anti-PD-1’

November 14th, 2014

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers

By

By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin cancer are diagnosed each year.2 Rates of melanoma—the deadliest form of skin cancer—are on the rise,2 particularly […]

View full entry

Tags: anti-PD-1, basal cell, General Skin Cancer, keytruda, Melanoma, News, pembrolizumab, Recurrent Melanoma, Skin Cancer, Skin Cancer Overview, Stage III Melanoma, Stage IV Melanoma


September 5th, 2014

Pembrolizumab Gets FDA Approval in Advanced Melanoma

By

The U.S. Food & Drug Administration (FDA) has granted approval to Merck’s new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma.   It is the first anti-PD-1 drug, aimed at re-energizing a patient’s protective immune response to cancer to have received FDA approval in the U.S. Of the more than one million new diagnoses of skin […]

View full entry

Tags: anti-PD-1, Melanoma, News, pembrolizumab, Recurrent Melanoma, Stage IV Melanoma